FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282971386> ?p ?o ?g. }

• W4282971386 endingPage "214" @default.
• W4282971386 startingPage "203" @default.
• W4282971386 abstract "Amantadine extended release (ER) [GOCOVRI®], an NMDA receptor antagonist, is an important treatment option in the management of levodopa-induced dyskinesia (LID) and OFF episodes in patients with Parkinson’s disease (PD). Taken at bedtime, amantadine ER provides low plasma levels overnight and high plasma concentrations during the waking day (i.e. delayed release). In randomized, double-blind, placebo-controlled phase III trials in adults with PD, once-daily amantadine ER was effective in improving LID, reducing OFF time and increasing ON time without troublesome dyskinesia, compared with placebo. Control of motor complications with amantadine ER was evident throughout the day, with fewer transitions between motor states. The clinical benefits of amantadine ER in reducing the duration and impact of dyskinesia and OFF episodes were durable with long-term treatment. Amantadine ER is generally well tolerated, including in the long term, with the majority of adverse events being mild or moderate in severity. Parkinson’s disease (PD), a common neurodegenerative disease, is associated with motor and non-motor symptoms and thus exerts a considerable burden on the health system. Levodopa is considered the gold standard treatment for PD; however, prolonged use is associated with reduced efficacy in the setting of more advanced disease and the emergence of motor complications of dyskinesia and OFF episodes. Management of these motor complications often involves the trade-off between treating one or the other. Amantadine extended release (ER) capsules (GOCOVRI®), administered once daily at bedtime, are the first to be approved in the USA to treat both dyskinesia and OFF episodes in PD. Evidence for the efficacy of amantadine ER has been demonstrated in two randomized, placebo-controlled phase III trials in PD patients with levodopa-induced dyskinesia (LID), where it reduced dyskinesia and OFF time and increased ON time without troublesome dyskinesia, relative to placebo. Benefits with amantadine ER were durable over long-term treatment. Amantadine ER is generally well tolerated in patients with LID, with no new safety concerns identified during longer-term use. Given its efficacy and tolerability profile, amantadine ER is an important treatment option for the management of LID and OFF episodes in PD patients." @default.
• W4282971386 created "2022-06-17" @default.
• W4282971386 creator A5067654964 @default.
• W4282971386 date "2022-05-01" @default.
• W4282971386 modified "2023-10-10" @default.
• W4282971386 title "Amantadine extended release capsules (GOCOVRI®) in Parkinson’s disease: a profile of its use in the USA" @default.
• W4282971386 cites W1727176495 @default.
• W4282971386 cites W1952327193 @default.
• W4282971386 cites W1981292076 @default.
• W4282971386 cites W1982638384 @default.
• W4282971386 cites W2003066583 @default.
• W4282971386 cites W2020789218 @default.
• W4282971386 cites W2046010854 @default.
• W4282971386 cites W2073486423 @default.
• W4282971386 cites W2115222037 @default.
• W4282971386 cites W2156411508 @default.
• W4282971386 cites W2338067045 @default.
• W4282971386 cites W2590370461 @default.
• W4282971386 cites W2621548695 @default.
• W4282971386 cites W2747038847 @default.
• W4282971386 cites W2789703631 @default.
• W4282971386 cites W2792548008 @default.
• W4282971386 cites W2804952730 @default.
• W4282971386 cites W2885668430 @default.
• W4282971386 cites W2889978819 @default.
• W4282971386 cites W2943895260 @default.
• W4282971386 cites W2963881455 @default.
• W4282971386 cites W2968987057 @default.
• W4282971386 cites W3000695970 @default.
• W4282971386 cites W3047352432 @default.
• W4282971386 cites W3142666124 @default.
• W4282971386 cites W3152444493 @default.
• W4282971386 cites W3153563356 @default.
• W4282971386 cites W3165772733 @default.
• W4282971386 cites W3194041306 @default.
• W4282971386 cites W4220802027 @default.
• W4282971386 cites W4225910232 @default.
• W4282971386 doi "https://doi.org/10.1007/s40267-022-00912-y" @default.
• W4282971386 hasPublicationYear "2022" @default.
• W4282971386 type Work @default.
• W4282971386 citedByCount "1" @default.
• W4282971386 countsByYear W42829713862023 @default.
• W4282971386 crossrefType "journal-article" @default.
• W4282971386 hasAuthorship W4282971386A5067654964 @default.
• W4282971386 hasBestOaLocation W42829713861 @default.
• W4282971386 hasConcept C126322002 @default.
• W4282971386 hasConcept C142724271 @default.
• W4282971386 hasConcept C197934379 @default.
• W4282971386 hasConcept C204787440 @default.
• W4282971386 hasConcept C27081682 @default.
• W4282971386 hasConcept C2777374534 @default.
• W4282971386 hasConcept C2778537899 @default.
• W4282971386 hasConcept C2779134260 @default.
• W4282971386 hasConcept C2779734285 @default.
• W4282971386 hasConcept C2780304432 @default.
• W4282971386 hasConcept C2780405171 @default.
• W4282971386 hasConcept C42219234 @default.
• W4282971386 hasConcept C71924100 @default.
• W4282971386 hasConcept C98274493 @default.
• W4282971386 hasConceptScore W4282971386C126322002 @default.
• W4282971386 hasConceptScore W4282971386C142724271 @default.
• W4282971386 hasConceptScore W4282971386C197934379 @default.
• W4282971386 hasConceptScore W4282971386C204787440 @default.
• W4282971386 hasConceptScore W4282971386C27081682 @default.
• W4282971386 hasConceptScore W4282971386C2777374534 @default.
• W4282971386 hasConceptScore W4282971386C2778537899 @default.
• W4282971386 hasConceptScore W4282971386C2779134260 @default.
• W4282971386 hasConceptScore W4282971386C2779734285 @default.
• W4282971386 hasConceptScore W4282971386C2780304432 @default.
• W4282971386 hasConceptScore W4282971386C2780405171 @default.
• W4282971386 hasConceptScore W4282971386C42219234 @default.
• W4282971386 hasConceptScore W4282971386C71924100 @default.
• W4282971386 hasConceptScore W4282971386C98274493 @default.
• W4282971386 hasIssue "5" @default.
• W4282971386 hasLocation W42829713861 @default.
• W4282971386 hasLocation W42829713862 @default.
• W4282971386 hasOpenAccess W4282971386 @default.
• W4282971386 hasPrimaryLocation W42829713861 @default.
• W4282971386 hasRelatedWork W1970320862 @default.
• W4282971386 hasRelatedWork W1976645888 @default.
• W4282971386 hasRelatedWork W2443034916 @default.
• W4282971386 hasRelatedWork W2460545767 @default.
• W4282971386 hasRelatedWork W2789738378 @default.
• W4282971386 hasRelatedWork W2886637474 @default.
• W4282971386 hasRelatedWork W2972225004 @default.
• W4282971386 hasRelatedWork W4206871429 @default.
• W4282971386 hasRelatedWork W4241238407 @default.
• W4282971386 hasRelatedWork W4299606317 @default.
• W4282971386 hasVolume "38" @default.
• W4282971386 isParatext "false" @default.
• W4282971386 isRetracted "false" @default.
• W4282971386 workType "article" @default.